Results 11 to 20 of about 13,912 (195)

Amodiaquine Enhances Anti‐Melanoma Efficacy of Attenuated Salmonella via Targeting Glutathione Reductase in Neutrophils

Advanced Science
Attenuated Salmonella VNP20009 (VNP) induces significant neutrophil recruitment in the tumor microenvironment (TME) during cancer therapy. However, the exact role of neutrophils in VNP‐mediated antitumor effects remains elusive. Here, we first identified
Wanfa Dong, Chunyuan Zhao, Chengxi Li, Lin Weng, Zehan Ji, Peiqi Li, Jiqiang Lu, Danni Liu, Anni Yu, Tianyi Jiang, Shaokai Huang, Heng Liu, Xiao Chen, Zichun Hua   +13 more
doaj   +2 more sources

Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination [PDF]

Malaria Journal, 2009
Background Artemisinin combination therapy (ACT) has been widely adopted as first-line treatment for uncomplicated falciparum malaria. In Uganda, amodiaquine plus artesunate (AQ+AS), is the alternative first-line regimen to Coartem® (artemether ...
Gustafsson Lars L, Mahindi Margarita, Mukonzo Jackson, Obua Celestino, Ntale Muhammad, Beck Olof, Ogwal-Okeng Jasper W   +6 more
doaj   +4 more sources

Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. [PDF]

Br J Clin Pharmacol
Aims Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar ...
Ding J, Hoglund RM, van der Pluijm RW, Callery JJ, Peto TJ, Tripura R, Das S, Châu NH, Promnarate C, Mukaka M, Dysoley L, Fanello C, Onyamboko MA, Anvikar AR, Mayxay M, Smithuis F, von Seidlein L, Dhorda M, Amaratunga C, Faiz MA, Nghia HDT, White NJ, Day NPJ, Dondorp AM, Tarning J.   +24 more
europepmc   +2 more sources

Sulfadoxine-pyrimethamine–based combinations for malaria : a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi [PDF]

, 2008
Background: In Malawi, there has been a return of Plasmodium falciparum sensitivity to chloroquine (CQ) since sulfadoxinepyrimethamine (SP) replaced CQ as first line treatment for uncomplicated malaria.
David J. Bell, Suzgo K. Nyirongo, Mavuto Mukaka, Ed E. Zijlstra, Christopher V. Plowe, Malcolm E. Molyneux, Steve A. Ward, Peter A. Winstanley, Aric Gregson, CV Plowe, MK Laufer, P Olumese, CO Obonyo, P Brasseur, AF Gasasira, CS Hatton, KA Neftel, P Olliaro, AA Djimde, JG Kublin, CV Plowe, A Cattamanchi, JG Kublin, TO Abuya, SR Hawley, G Dorsey, CE Rwagacondo, WM Watkins, CT Happi, GS Humphreys, SL Nsobya, I Zongo, C Dokomajilar, C Sisowath, MT Duraisingh, AP Alker, PA Phillips-Howard, D Douer, R Carr, EG Rhodes, ME Ellis   +40 more
core   +22 more sources

Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023. [PDF]

Trop Med Int Health
ABSTRACT Objectives Artemisinin partial resistance has emerged in East Africa and is feared to spread across the continent, potentially compromising artemisinin‐based combination treatment. Molecular markers can serve as early warning signals for the development of specific drug resistance.
Kegya AD, Oppong E, Darko E, Boateng KA, Phillips RO, Heinemann M, Ramharter M, Igiraneza C, Ndoli JM, Mockenhaupt FP, van Loon W.   +10 more
europepmc   +2 more sources

Amodiaquine-Associated Asthenia: A Case Based Review and Gaps in Literature [PDF]

International Journal of Travel Medicine and Global Health, 2016
Introduction: Amodiaquine is a partner drug in the artemisinin-based combination therapy artesunate-amodiaquine. Reports of the adverse drug reaction known as amodiaquine-associated asthenia are scarce, and this adverse reaction needs to be investigated ...
Obaro Michael, Joseph Badejo, Adewale Bakre, Adebola Orimadegun, Olusegun Ademowo, Catherine Falade   +5 more
doaj   +1 more source

Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment

Pharmaceutics, 2023
The objective of this study was to construct amodiaquine-loaded, folic acid-conjugated polymeric nanoparticles (FA-AQ NPs) to treat cancer that could be scaled to commercial production.
Vineela Parvathaneni, Snehal K. Shukla, Vivek Gupta   +2 more
doaj   +1 more source

The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis.

PLoS Medicine, 2021
BackgroundAmodiaquine is a 4-aminoquinoline antimalarial similar to chloroquine that is used extensively for the treatment and prevention of malaria.
Xin Hui S Chan, Ilsa L Haeusler, Yan Naung Win, James Pike, Borimas Hanboonkunupakarn, Maryam Hanafiah, Sue J Lee, Abdoulaye Djimdé, Caterina I Fanello, Jean-René Kiechel, Marcus Vg Lacerda, Bernhards Ogutu, Marie A Onyamboko, André M Siqueira, Elizabeth A Ashley, Walter Rj Taylor, Nicholas J White   +16 more
doaj   +1 more source

Low efficacy of the combination artesunate plus amodiaquine for uncomplicated falciparum malaria among children under 5 years in Kailahun, Sierra Leone. [PDF]

, 2006
OBJECTIVE: In 2004, Sierra Leone adopted artesunate plus amodiaquine as first-line antimalarial treatment. We evaluated the efficacy of this combination in Kailahun, where a previous study had shown 70.2% efficacy of amodiaquine in monotherapy.
Balkan, S, Checchi, F, Durand, R, Grandesso, F, Guthmann, J P, Hagerman, A, Kamara, S, Lam, E, Scollo, G   +8 more
core   +2 more sources

Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. [PDF]

, 2014
Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P.
Adam, Ishag, Ademowo, George, Arze, Cesar, Asaq Molecular Marker Study Group, Baliraine, Frederick N, Berens-Riha, Nicole, Björkman, Anders, Borrmann, Steffen, Checchi, Francesco, Dahal, Prabin, Davis, Timothy ME, Desai, Meghna, Dhorda, Mehul, Djimdé, Abdoulaye A, Dorsey, Grant, El-Sayed, Badria B, Eshetu, Teferi, Eyase, Frederick, Falade, Catherine, Faucher, Jean-François, Fröberg, Gabrielle, Gadalla, Nahla B, Grivoyannis, Anastasia, Guérin, Philippe, Hamour, Sally, Houzé, Sandrine, Johnson, Jacob, Kamugisha, Erasmus, Kariuki, Simon, Kiechel, Jean-René, Kironde, Fred, Kofoed, Poul-Erik, LeBras, Jacques, Malmberg, Maja, Moriera, Clarissa, Mwai, Leah, Mårtensson, Andreas, Ménard, Didier, Ngasala, Billy, Nosten, Francois, Nsanzabana, Christian, Nsobya, Samuel L, Nzila, Alexis, Oguike, Mary, Ogutu, Bernhards, Otienoburu, Sabina Dahlström, Ouédraogo, Jean-Bosco, Piola, Patrice, Plowe, Christopher V, Price, Ric N, Rombo, Lars, Rosenthal, Philip J, Schramm, Birgit, Sibley, Carol Hopkins, Somé, A Fabrice, Stepniewska, Kasia, Sutherland, Colin J, Thwing, Julie, Ursing, Johan, Venkatesan, Meera, Wong, Rina PM, Zeynudin, Ahmed, Zongo, Issaka   +62 more
core   +4 more sources